6/30/2020 8:15:21 AM
Rubius CFO Andrew Oh To Depart; Update On Clinical Trial Progress For RTX-240
1/8/2020 8:19:44 AM
Rubius Therapeutics Names Laurence Turka Chief Scientific Officer
12/23/2019 8:09:29 AM
Rubius Therapeutics Appoints Christina Coughlin As Chief Medical Officer
12/18/2019 8:07:12 AM
Rubius Therapeutics Appoints Anne Prener To Its Board
11/14/2019 8:07:04 AM
Rubius Therapeutics Q3 Net Loss $47.0 Mln Or $0.59 Per Share
11/4/2019 8:06:18 AM
Entrada Therapeutics Names Nathan Dowden COO
1/8/2019 8:07:13 AM
Cygnal Therapeutics Appoints Pearl Huang As CEO
11/13/2018 8:25:01 AM
Rubius Therapeutics Q3 Net Loss $26.4 Mln Vs. $11.9 Mln Last Year
8/31/2018 8:03:19 AM
Rubius Therapeutics Q2 Loss Per Share $3.33 Vs Loss $1.25 Last Year
8/13/2018 6:49:35 AM
Jefferies Starts Rubius Therapeutics (RUBY) At Buy With $40 Price Target
7/25/2018 8:35:14 AM
Rubius To Acquire Manufacturing Facility In Smithfield, Rhode Island To Produce Red Cell Therapeutics
7/23/2018 8:40:04 AM
Rubius Therapeutics Closes IPO Of 12.06 Mln Shares Of Common Stock At $23/Shr
7/17/2018 10:45:58 PM
Rubius Therapeutics Announces Pricing Of IPO Of 10.48 Mln Shares At $23.00/shr